Clinical Trial

Salivary Replication of BK Virus in Post-kidney Transplant

Study acronym: BKSAL
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
BK virus infection in kidney transplantation can compromise graft function. Current data suggest that BK virus nephropathy results not only from transmission of virus from the donor but also from reactivation of latent virus in the recipient. However, no study has investigated the possibility of respiratory transmission. This study would provide a better understanding of the pathophysiology of BK virus infection in kidney transplant recipients. The investigators would study viral replication of BK virus in saliva, urine and blood of patients who received a kidney transplant at the Amiens University Hospital. For this, the investigators will collect salivary self-collection on the day of the kidney transplant then at 1, 3, 6, 9 and 12 months as well as a urine and blood sample. The investigators will measure BK viral load in these three samples at different times.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-20.
Trial Details
NCT Number NCT07256470
Lead Sponsor Centre Hospitalier Universitaire, Amiens
Conditions BK Virus, Salivary Replication, Kidney Transplantation, Nephropathy, DNAemia
Enrollment 100 participants
Start Date 2025-12
Primary Completion 2027-04 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-08